# COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

Study · id `cardio:ct-nct04642430` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04642430](<https://clinicaltrials.gov/study/NCT04642430>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04642430

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3018 participants.

## Technical summary

Registry record NCT04642430. Randomized; single masking; primary purpose treatment. Start 2021-07-06 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3018 participants (planned count; ClinicalTrials.gov record NCT04642430, source copy `cardio:ctgov-nct04642430-2026-10-01`, retrieved 2026-10-26)
- Started: 2021-07-06 (actual) (ClinicalTrials.gov record NCT04642430, source copy `cardio:ctgov-nct04642430-2026-10-01`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT04642430, source copy `cardio:ctgov-nct04642430-2026-10-01`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT04642430, source copy `cardio:ctgov-nct04642430-2026-10-01`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT04642430, source copy `cardio:ctgov-nct04642430-2026-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04642430-2026-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
- Acronym: COBRRA-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): Apixaban
- Intervention (Drug): Rivaroxaban
- Lead sponsor: Ottawa Hospital Research Institute
- Lead sponsor class: OTHER
- Collaborator: Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
- Collaborator class: NETWORK
- Collaborator: Canadian Institutes of Health Research (CIHR)
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Ottawa Hospital Research Institute (`cardio:org-ottawa-hospital-research-institute`)
- Registry lists this organization as a collaborator: Canadian Institutes of Health Research (CIHR) (`cardio:org-canadian-institutes-of-health-research-cihr`)

## Provenance

Content hash: c3ca09cce8bb0ef3e24730d36b1ab36aa6a283a83ece604560cb72e2c759beca
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
